MBX (MBX Biosciences, Inc.) Aggregate Asset Value

MBX (MBX Biosciences, Inc.) - company brandmark

The price action of MBX Biosciences Inc (MBX) total assets is 333.73. The business is currently spending significant funds on research, meaning profits remain limited pending regulatory verdicts. MBX Biosciences Inc (MBX) is developing precision peptide therapies via the PEP system, aiming for partnerships with industry behemoths. Demand for such medications is stable; therefore, the project's success depends on medical outcomes rather than economic conditions.

mbxbio.com (MBX) Aggregate Company Assets: for the period 09/14/2024 - 10/30/2026

Financial and market metric breakdowns for MBX Bio (MBX)

- current price and projected stock value:
Quote Chart mbxbio.com|MBX - Analyst Consensus Forecast
- business market valuation indicators:
Market Value MBX Corp|MBX - Enterprise Value
- business book valuation details:
Book Value per Share MBX Biosciences|MBX - Company Book Value|Market Value to Book Value mbxbio.com|MBX - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio MBX Biosciences Inc|MBX - Long-Term Debt to Capital|Short-Term Debt to Capital MBX Corp|MBX - Company Total Debt|Debt to Net Assets Ratio MBX Corp|MBX - Company Long-Term Debt|Company Current Liabilities MBX Biosciences|Immediate Liquidity mbxbio.com
- earnings and market multiples details:
MBX - Net Income
Summary company analysis:mbxbio.com (MBX)
Core merchandise of MBX Bio

Effective management of endocrine developments at MBX Biosciences Inc (MBX) requires strict resource control to execute clinical stages. The dynamics of this indicator, calculated inversely through return on assets (ROA), reflect the sum of equity and liabilities. This metric measures the total volume of controlled assets, allowing for the separation of real base growth from speculative fluctuations. By analyzing the organization's asset level, an investor can assess the financial discipline and resilience of the business.

Main competitors

Total Asset Value of Company ASND (ascendispharma.com)|MDGL (Madrigal Pharmaceuticals, Inc.) - Company Total Assets|CORT: Aggregate Asset Value|Company Total Assets RYTM|Company Total Assets Akero Corp (AKRO)|Aggregate Company Assets Metsera Inc MTSR|Aggregate Asset Value MLTX|CRNX - Aggregate Company Assets|NewAmsterdam Pharma Company (NAMS) - Cumulative Company Assets|SLNO: Company Total Assets|Amicus Corp (FOLD) - Company Total Assets|Cumulative Company Assets ETNB|AGIO: Aggregate Asset Value|Aggregate Company Assets Structure Therapeutics Inc. (GPCR)|Cumulative Company Assets MiMedx Group Inc MDXG|Company Total Assets RZLT (Rezolute Corp)|Lexicon Corp (LXRX) - Company Assets|ALT: Cumulative Company Assets|aardvarktherapeutics.com - Aggregate Business Assets|SGMT: Company Total Assets|BioAge Labs (BIOA) - Company Total Assets|BMEA (Biomea) - Company Total Assets|Aggregate Company Assets QNCX|Aggregate Company Assets Fractyl Health, Inc. (GUTS)|VTVT - Company Assets|Aggregate Company Assets Agape ATP ATPC|Pluristem Therapeutics - Aggregate Company Assets|Synlogic Corp - Company Total Assets|Company Total Asset Base Lipocine Corporation LPCN|matinasbiopharma.com (MTNB) - Aggregate Company Assets|SPRB - Company Total Asset Base|Aggregate Company Assets Galecto|Cumulative Company Assets Carmell Corp. (CTCX)|Aggregate Company Assets Lumos Pharma Corp (LUMO)|Cumulative Company Assets Organovo Corp ONVO|Company Total Assets RDUS (Radius Recycling, Inc.)